Mylan |

Mylan engages in the development, manufacture and distribution of generic medical products.

What section would you like to update?
  • Company Logo
  • Company Name & URL
  • Company Description
  • Founded Date
  • Company Status
  • HQ Address
  • Social Links
  • CEO Name & Picture
  • Competitor Set
  • Funding Events
  • Acquisition Events

If you'd like to make any changes to this portfolio we'd be happy to help. Please send info/sources to support@owler.com.


We'll be back up as soon as possible.

Visit owler.uservoice.com for FAQs

Mylan Revenue, Funding, Number of Employees, Competitors and Acquisitions

MYLAN CEO

Heather Bresch

CEO

Heather Bresch

Approval Rating: 42/100

WEIGH-IN

How would you rate Heather Bresch as a CEO?

negative
You
neutral
You
positive
You

Founded:

1961

Headquarters:

CanonsburgPennsylvania

Status:

PublicNASDAQMYL

Industry Sector:

Pharmaceuticals

Completeness:

100%

KEY STATS

Revenue

- -

What is Mylan's revenue?

<1M

Employees

- -

How many people work at Mylan?

Followers on Owler

- -

FOLLOW
UNFOLLOW

TOP COMPETITORS

Add a new competitor:

Thanks for your contribution!

Recalculating The Competitive Graph now...

ADD

Mylan was founded in 1961 and its headquarters is located in Canonsburg, Pennsylvania, USA. Mylan has $8.4B in revenue and 35000 employees. Mylan's top competitors are TEVA Pharmaceuticals, Par Pharmaceutical and Sagent Pharmaceuticals.

Mylan Competitive Set

COMPANYLEADERSHIPCEO SCORE

EMPLOYEES
(ESTIMATED IF PRIVATE)

TOTAL FUNDING

REVENUE
(ESTIMATED IF PRIVATE)

LIKELY OUTCOME
MylanMylan ceo

Heather Bresch

CEO

42/100
1TEVA Pharmaceuticals ceoTEVA Pharmaceuticals

Kaare Schultz

President & CEO

51/10051,800
$22.4B
2Par Pharmaceutical ceoPar Pharmaceutical

1,600
$1.4B
3Sagent Pharmaceuticals ceoSagent Pharmaceuticals

Allan Oberman

CEO

60/100440$162M$297.8M
4Mallinckrodt Pharmaceuticals ceoMallinckrodt Pharmaceuticals

Mark Trudeau

President & CEO

55/1004,500
$3.3B
5Upsher-Smith ceoUpsher-Smith

Mark Evenstad

President & CEO

72/10010,000
$190M
6Taro ceoTaro

Uday Baldota

CEO

85/1001,413
$879.4M
7Aurobindo Pharma ceoAurobindo Pharma

Govindarajan Narayanan

Managing Director

74/10013,288
$1.6B
8Cipla ceoCipla

Umang Vohra

CEO

65/10023,043
$2.3B

Mylan Revenue History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

$

Community Estimate

UPDATE THIS

Mylan Employee History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

Community Estimate

UPDATE THIS

Mylan Leadership

NAMETITLESOCIAL MEDIA
Heather Bresch
Heather Bresch

CEO

CEO

Mylan Acquisitions

COMPANY ACQUIRED ACQUISITION DATEAMOUNTDESCRIPTION
Cold-EEZECold-EEZEJan 201750MCold-EEZE develops and manufactures zinc gluconate products for cold and throat problems.
Meda ABMeda ABFeb 20167.2BMeda is a developer and marketer of respiratory, dermatology, pain and inflammation therapy products.
undefinedDec 2011undisclosed

Mylan has acquired 3 companies.Mylan's latest acquisition was Cold-EEZE in Jan 2017. Cold-EEZE develops and manufactures zinc gluconate products for cold and throat problems.

Mylan Funding History

Since Mylan was founded in 1961, it has participated in 1 round of funding. In total Mylan has raised $0. Mylan's funding round was on Feb 1973 for a total of $0

ROUNDFUNDING DATE AMOUNTINVESTORS
IPOFeb 1973$

Total: $

Mylan News

Mylan: Mylan launches first followon glatiramer acetate in the UKUS generics giant Mylan announced on 23 January 2018 that it had launched Brabio the first followon version of Teva Pharmaceuticals Teva Copaxone glatiramer acetate in the UK.BioPortfolio
Press Release: Mylan : Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018HERTFORDSHIRE, England, and PITTSBURGH, Feb. 8, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will release its fourth quarter and full year 2017 financial results, as well as its 2018 financial guidance, on Wednesday, Feb. 28, following the close of the U.S....PR Newswire
Mylan: BRIEF-Mylan Expands Access To HIV/AIDS Medicines With Launch Of First Generic Sustiva Tablets* MYLAN EXPANDS ACCESS TO HIV/AIDS MEDICINES WITH LAUNCH OF FIRST GENERIC SUSTIVA® TABLETSReuters
Mylan: Mylan And Theravance NDA Okayed For Adults With COPDNewsIf approved, revefenacin would be the first once-daily, nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD). FDA assigned a PDUFA target action date of November 13, 2018.Contributed Author: Mylan N.V.Topics: Drug DevelopmentPharmaceutical Processing
Mylan: Mylan (MYL) & Biocon Announce Positive CHMP Opinion for SemgleeMylan N.V. (NASDAQ: MYL) and Biocon Ltd. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Semglee™, insulin glargine, a long-acting insulin analog used in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.StreetInsider
Mylan: One size of EpiPen to treat life-threatening allergic reactions in short supply, distributor says Health Canada advises anyone having an anaphylactic reaction to use their expired product and immediately call 911. The shortage isn't affecting EpiPen Jr.Toronto Star
Press Release: Mylan : Global Angina Pectoris Drugs Market 2017 by Manufacturers - Gilead, Pfizer, Merck, Novartis, MylanThe Global Angina Pectoris Drugs Market 2017 report recognizes a rising focus on thorough study of the most important factors that are essential to increase the growth, sales as well as awareness of the market across the world. This comprehensive report also involves forecasts for the Global Angina Pectoris Drugs Market from 2017 to 2011. [...]The post Global Angina Pectoris Drugs Market 2017 by Manufacturers - Gilead, Pfizer, Merck, Novartis, Mylan appeared first on ePressRelease.ePress Release
Mylan: BRIEF-Tax reform relatively neutral for Mylan-CFO* SAYS ITS BIOSIMILAR FOR AMGEN'S NEULASTA COULD BE A "MID-YEAR OPPORTUNITY"Reuters
Mylan: Mylan NV MYL Medical Equipment Deals and Alliances Profile Report Updated 21122017 Prices from USD $250SummaryMylan NV Mylan is a pharmaceutical company which develops licenses manufactures markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categorie...BioPortfolio
Mylan: Mylan (MYL) Completing Prior $1B Share Repurchase PlanMylan N.V. (NASDAQ: MYL) today announced that it is completing its previously-approved $1 billion share repurchase plan.StreetInsider

SEE MORE

SEE LESS

Mylan Website History

Screengrabs of how the Mylan site has evloved. (Click to expand)

Mylan website history

Sep 2017

Mylan website history

Sep 2017

Mylan website history

May 2017

Mylan website history

Jan 2017

Mylan website history

Oct 2016

Mylan website history

Jul 2016

Mylan website history

Apr 2016

Mylan website history

Jan 2016

Mylan website history

Oct 2015

Mylan website history

Jul 2015

Mylan website history

Apr 2015

Mylan website history

Nov 2014

Mylan website history

Aug 2014

Mylan website history

May 2014

Mylan website history

Mar 2013

Mylan website history

Jan 2013

Owler has collected 16 screenshots of Mylan's website since Jan 2013. The latest Mylan website design screenshot was captured in Sep 2017.

Mylan Headquarters

undefined company logo

1000 Mylan Blvd

Canonsburg, Pennsylvania 15317

724-514-1800

Driving Directions

google map

Mylan Summary Information

Mylan engages in the development, manufacture and distribution of generic medical products. Mylan was founded in 1961. Mylan's headquarters is located in Canonsburg, Pennsylvania, USA 15317. It has raised undisclosed amount in 1 round. The latest round was in Feb 1973. Mylan's primary investor is . Mylan's latest acquisitions include Cold-EEZE, Meda AB and . Mylan's CEO, Heather Bresch, currently has an approval rating of 42%. 61% of Owler community believes the stock will go Down. Mylan has 35000 employees and reported 8.4B in revenue [trailing four quarters].

Mylan's CEO, Heather Bresch, currently has an approval rating of 42%. Mylan's primary competitors are  TEVA Pharmaceuticals Par Pharmaceutical Sagent Pharmaceuticals.

Visit the Mylan website to learn more.